DDInter1824 DDInter1147
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tociliz
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Tocilizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Tocilizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isradipine
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dienogest
Tocilizumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tocilizumab {u} may lead to a major life threatening interaction when taken with {v} Canakinumab
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Isradipine
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Tocilizumab may lead to a major life threatening interaction when taken with Fingolimod
Tocilizumab may lead to a major life threatening interaction when taken with Canakinumab